私たちは抗体の発現、開発、最適化に注力し、先進的な自動化生産ラインを持ち、競争力のある価格と効率的なリードタイムを提供できます。
私たちはECACCからライセンスされたCHOK1BN細胞株の商業化に関する排他的な再ライセンス権を保有しています。
私たちの2,000+のグローバルなバイオテクノロジー企業や製薬企業とのパートナーシップになり、そして、国際的な臨床段階での共同の進歩と結びついています。
私たちは、お客様に提供した抗体の所有権を守り、機密情報の保持をお約束します。
This report aims to explore the events and trends of the biopharmaceutical industry in Q2 (April, May, June). Besides crovalimab and Vyloy, two more novel antibody drugs have been approved this year
Antibody specificity refers to an antibody's ability to selectively bind to a unique epitope on a target antigen while avoiding interactions with unrelated antigens. This property arises from the highly specialized antigen-binding site located in the variable region of the antibody, which determines its unique binding characteristics.
Antibody affinity refers to the strength of the binding interaction between a single antigen epitope and the paratope (binding site) of an antibody. This interaction is a fundamental measure of how well an antibody recognizes its specific antigen target.
In March 2024, Cyagen and Biointron officially signed off on their strategic partnership, forging an alliance in antibody drug development. This partnership aims to fully leverage the strengths of Cyagen's HUGO-Ab™ fully humanized mouse antibody discovery platform and Biointron&#
Biointron is proud to announce a strategic partnership with FatiAbGen, a leading biotechnology firm focused on antibody-based therapeutics. As the newly appointed Korean distributor for Biointron, FatiAbGen will be at the forefront of delivering Biointron’s products to the Korean market.
Biointron is proud to announce our sponsorship of the highly anticipated Chinese Antibody Society 2024 mAbTalk Symposium.
Biointron is thrilled to announce our participation in the Immuno-Oncology Summit 2024! Mark your calendars for August 7 - 9 and join us at Hilton Philadelphia at Penn's Landing, PA, for this premier event dedicated to the latest advancements in immuno-oncology.
We are excited to announce that Biointron will be participating in BIOPLUS-INTERPHEX KOREA 2024, which will take place from July 10 - 12, 2024, at COEX, Seoul, South Korea. This prestigious event is a key gathering for professionals in the biopharmaceutical and biotechnology industries, and we look forward to showcasing our latest advancements and engaging with industry leaders.
ScientistとScience Exchangeとのご利用可能です。
